Vera Therapeutics (VERA) Stock News

Vera Therapeutics (Nasdaq: VERA) reported significant progress in Q2 2025, highlighted by positive results from their pivotal ORIGIN 3 trial for atacicept in IgA Nephropathy (IgAN) treatment. The trial achieved its primary endpoint with a 42% reduction in UPCR compared to placebo (p<0.0001), and participants showed a 46% reduction in proteinuria from baseline.

The company plans to submit a Biologics License Application (BLA) for atacicept to the FDA in Q4 2025, targeting commercial launch in 2026. Vera also initiated the PIONEER trial to evaluate atacicept in expanded patient populations. Financially, Vera secured a $500 million credit facility with Oxford Finance LLC and reported $556.8 million in cash and equivalents, ensuring funding through potential commercial launch.

Vera Therapeutics (Nasdaq: VERA) announced inducement grants to fifteen new employees under its Inducement Plan, approved by the Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).

The grants include non-qualified stock options to purchase 133,500 shares of Class A common stock at $24.00 per share and restricted stock units (RSUs) for 73,695 shares. The stock options will vest over four years, with 25% vesting after one year and the remainder monthly over 36 months. RSUs will vest 25% annually over four years starting August 20, 2025.

Vera Therapeutics announced inducement grants to 17 new employees on June 3, 2025. The grants include non-qualified stock options to purchase 124,000 shares of Class A common stock at $30.91 per share and RSUs for 65,925 shares. The stock options will vest over 4 years, with 25% vesting after the first year and the remainder vesting monthly over 36 months. The RSUs will vest over 4 years, with 25% vesting annually starting August 20, 2025. These awards were approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4) as inducement material for new employee employment.

Vera Therapeutics (NASDAQ: VERA), a late clinical-stage biotech company specializing in immunological disease treatments, announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference. The event will be held in Miami Beach, FL from June 9-11, 2025. The company's management team will engage in a fireside chat scheduled for Wednesday, June 11, 2025, at 3:15pm EDT, and will also conduct one-on-one investor meetings. A webcast of the presentation will be available through the company's website, with replay access lasting 90 days in the "Investor Calendar" section.

Vera Therapeutics (VERA) has secured a new $500 million credit facility with Oxford Finance, replacing its existing $50 million facility. The initial funding of $75 million is set for June 4, 2025. The new facility features a reduced interest rate of SOFR plus 4.95% (320 basis points lower), with $450 million available in five tranches. Key features include a $50 million draw option through 2026, $75 million tied to atacicept's accelerated approval in IgAN, two $50 million tranches post-approval, and $200 million at mutual discretion. The refinancing extends the interest-only period by 42 months and maturity by 41 months, eliminating 2026 principal payments. The company expects to submit a BLA for atacicept to the FDA in Q4 2025, targeting potential approval and launch in 2026.

Vera Therapeutics (NASDAQ: VERA) announced positive results from its ORIGIN Phase 3 trial of atacicept for treating IgA nephropathy (IgAN) in adults. The trial met its primary endpoint with atacicept achieving a significant 46% reduction in proteinuria from baseline and 42% reduction compared to placebo at week 36 (p<0.0001). The safety profile was favorable and comparable to placebo. Based on these promising results, Vera plans to submit a Biologics License Application (BLA) for accelerated approval to the FDA in Q4 2025, potentially leading to approval and commercial launch in 2026. The ORIGIN 3 trial, involving 431 adults, continues in a placebo-controlled manner to evaluate kidney function changes over two years, with final results expected in 2027.

Vera Therapeutics (NASDAQ: VERA) announced inducement awards granted to eleven new employees on May 5, 2025. The awards include non-qualified stock options to purchase 111,750 shares of Class A common stock and restricted stock units (RSUs) for 62,575 shares. The stock options have an exercise price of $25.53 per share, based on VERA's closing price on May 5.

The stock options will vest over 4 years, with 25% vesting on the first anniversary and the remainder vesting monthly over 36 months. The RSUs will vest over 4 years, with 25% vesting annually starting May 20, 2025. Both awards are contingent on continued employment with Vera.

Vera Therapeutics (NASDAQ: VERA) provided its Q1 2025 business update, highlighting significant progress in its atacicept development program. The company is approaching a crucial milestone with upcoming primary endpoint results from the pivotal Phase 3 ORIGIN trial for IgA Nephropathy (IgAN) in Q2 2025, followed by planned BLA submission to FDA in Q4 2025.

Financial results showed a net loss of $51.7 million ($0.81 per share) compared to $28.4 million ($0.56 per share) in Q1 2024. The company maintains a strong financial position with $589.8 million in cash and equivalents, deemed sufficient to fund operations through potential approval and U.S. commercial launch.

Vera has expanded its atacicept development program across multiple autoimmune kidney diseases and acquired rights to VT-109, a novel fusion protein targeting BAFF and APRIL.

Vera Therapeutics (VERA) announced inducement awards granted by its Compensation Committee on April 3, 2025, to sixteen new employees. The awards include:

• Non-qualified stock options to purchase 211,250 shares of Class A common stock at $22.74 per share
• Restricted stock units (RSUs) for 105,125 shares of Class A common stock

The stock options will vest over four years, with 25% vesting on the first anniversary and the remaining vesting monthly over 36 months. RSUs will vest over four years, with 25% vesting annually starting May 20, 2025. Both awards are subject to continued employment and the terms of the Inducement Plan.